検索
Pharvaris NV
PHVSウォッチリストに追加
33.950USD
-0.630-1.82%
終値 07/01, 16:00（ET）15分遅れの株価
2.22B時価総額
損失額直近12ヶ月PER
詳細情報 Pharvaris NV 企業名
Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.
Pharvaris NVの企業情報
企業コードPHVS
会社名Pharvaris NV
上場日Feb 05, 2021
最高経営責任者「CEO」Modig (Berndt B.A.E)
従業員数- -
証券種類Ordinary Share
決算期末Feb 05
本社所在地Emmy Noetherweg 2
都市LEIDEN
証券取引所NASDAQ OMX - NASDAQ BASIC
国Netherlands
郵便番号2333 BK
電話番号31712036410
ウェブサイトhttps://pharvaris.com/
企業コードPHVS
上場日Feb 05, 2021
最高経営責任者「CEO」Modig (Berndt B.A.E)
Pharvaris NVの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Berndt Modig, CPA
Mr. Berndt Modig, CPA
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
1.63M
-0.14%
Dr. Peng Lu, M.D., Ph.D.
Dr. Peng Lu, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
505.39K
-0.04%
Mr. David W. Nassif, J.D.
Mr. David W. Nassif, J.D.
Chief Financial Officer
Chief Financial Officer
191.62K
-5.22%
Dr. David P. Meeker ,M.D.
Dr. David P. Meeker ,M.D.
Non-Executive Director
Non-Executive Director
152.35K
+32.51%
Dr. Elisabeth Bjork, M.D., Ph.D.
Dr. Elisabeth Bjork, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
110.78K
--
Ms. Viviane Monges
Ms. Viviane Monges
Non-Executive Director
Non-Executive Director
96.45K
-10.02%
Ms. Anna Nijdam
Ms. Anna Nijdam
Head of Finance, Principal Accounting Officer
Head of Finance, Principal Accounting Officer
47.61K
-5.61%
Dr. Jochen Knolle, Ph.D.
Dr. Jochen Knolle, Ph.D.
Co-Founder, Chief Operating Officer, Chief Scientific Officer
Co-Founder, Chief Operating Officer, Chief Scientific Officer
--
--
Dr. Anne Lesage, Ph.D.
Dr. Anne Lesage, Ph.D.
Co-Founder, Chief Early Development Officer
Co-Founder, Chief Early Development Officer
--
--
Dr. Morgan Conn, Ph.D.
Dr. Morgan Conn, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Berndt Modig, CPA
Mr. Berndt Modig, CPA
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
1.63M
-0.14%
Dr. Peng Lu, M.D., Ph.D.
Dr. Peng Lu, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
505.39K
-0.04%
Mr. David W. Nassif, J.D.
Mr. David W. Nassif, J.D.
Chief Financial Officer
Chief Financial Officer
191.62K
-5.22%
Dr. David P. Meeker ,M.D.
Dr. David P. Meeker ,M.D.
Non-Executive Director
Non-Executive Director
152.35K
+32.51%
Dr. Elisabeth Bjork, M.D., Ph.D.
Dr. Elisabeth Bjork, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
110.78K
--
Ms. Viviane Monges
Ms. Viviane Monges
Non-Executive Director
Non-Executive Director
96.45K
-10.02%
よくある質問
Pharvaris NVの上位5名の株主は誰ですか？
Pharvaris NVの上位5名の株主は以下のとおりです。Mr. Berndt Modig, CPA
Pharvaris NV（PHVS）の株式を保有している機関の数はいくつですか？
2026Q1時点で、Pharvaris NVの株式を保有している機関は165社あり、保有株式の総市場価値は約59.26Mで、全体の90.60%を占めています。2025Q4と比較して、機関の持ち株は-451327.00増加しています。